At baseline, the medications for T2DM included metformin (45.6%), glucagon-like peptide-1 receptor agonists (39.7%), sodium-glucose co-transporter 2 inhibitors (36.8%), insulin (33.8%), and dipeptidyl peptidase-4 inhibitors (32.4%). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.